Alexandre Alexeyenko, MD
Internal Medicine · Lynn, MANPI 1568464279
Payments from drug & device makers
Across 37 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$232
- Boehringer Ingelheim$170
- Eisai Inc.$52
- Lilly USA, LLC$49
- AbbVie$38
- Otsuka America Pharmaceutical, Inc.$38
- plus $191 from 9 others
What the payments were for
- Food & beverage$769100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $232 |
| Boehringer Ingelheim | 6 | $170 |
| Eisai Inc. | 3 | $52 |
| Lilly USA, LLC | 3 | $49 |
| AbbVie | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Novo Nordisk | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 1 | $29 |
| Lundbeck LLC | 1 | $25 |
| Bayer | 1 | $23 |
| Exact Sciences | 1 | $17 |
| Novartis | 1 | $17 |
| GSK | 1 | $16 |
| Pfizer | 1 | $13 |
| Echosens North America, Inc. | 1 | $13 |
How this compares
$769 in reported general payments places this provider in the 80th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 306 | $184,834 |
| TrulicityDulaglutide | 166 | $175,360 |
| EliquisApixaban | 259 | $157,836 |
| XareltoRivaroxaban | 156 | $100,083 |
| OzempicSemaglutide | 82 | $86,592 |
| FarxigaDapagliflozin Propanediol | 103 | $64,353 |
| JanuviaSitagliptin Phosphate | 86 | $48,519 |
| LinzessLinaclotide | 87 | $46,641 |
| TradjentaLinagliptin | 80 | $42,086 |
| DapagliflozinDapagliflozin Propanediol | 62 | $33,698 |
| CreonLipase/Protease/Amylase | 68 | $29,489 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $28,309 |
| Droxidopa | 13 | $28,292 |
| MounjaroTirzepatide | 17 | $24,909 |
| Rosuvastatin Calcium | 1,736 | $20,743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $170 | $234,010400 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $49 | $200,269183 claims |
| PfizerEliquis | $13 | $157,836259 claims |
| Novo NordiskOzempic, Rybelsus | $36 | $106,040102 claims |
| AbbVieLinzess, Creon | $38 | $76,130155 claims |
| AstraZenecaFarxiga, Crestor | $232 | $71,716128 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $16 | $39,85466 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Lynn
- Noopur RajeBoston$19.9M
- Michael McCartneyNewburyport$17.6M
- Rebecca HeistBoston$17.4M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Joyce LiuCharlestown$10.3M
- Elizabeth LeeBoston$9.8M
- Adnan DahdulSpringfield$8.8M
- Ryan SullivanCambridge$8.5M
- Xiuning leBoston$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.